Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Seer (Nasdaq: SEER) said the U.S. Patent and Trademark Office Patent Trial and Appeal Board issued a Final Written Decision on March 23, 2026 upholding 23 claims of U.S. Patent No. 11,435,360, which protect its Proteograph nanoparticle protein enrichment methods.
The ’360 patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer; the decision affirms key claim coverage of Proteograph’s nano- and microparticle protein-corona technology.
Seer noted the platform is supported by an IP portfolio of more than 240 issued and pending patents, including 80 issued patents.
Summary not available.
Seer (Nasdaq: SEER) adopted a limited-duration tax benefit preservation plan to protect approximately $262 million of net operating loss carryforwards as of December 31, 2025. The plan seeks to limit ownership accumulation above 4.9% of Class A stock without Board approval.
The Board declared a dividend of one transferable right per outstanding Class A share, with a record date of March 9, 2026. The NOL Plan expires February 25, 2029, or earlier on February 25, 2027 if shareholders do not ratify it at Seer’s 2026 annual meeting.
Seer (Nasdaq: SEER) reported fourth-quarter and full-year 2025 results, with $4.2M revenue in Q4 and $16.6M for full year 2025. Installed base grew to 82 instruments (67% YoY) and year-end cash, cash equivalents and investments were approximately $240.6M.
Gross margin was ~51% for 2025, operating expenses fell to $86.5M, and net loss narrowed to $73.6M. Seer expects 2026 revenue of $16M–$18M (midpoint ~3% growth).
Radoff-JEC Group (owners of ~7.5% of SEER) sent an open letter to Seer (NASDAQ: SEER) on February 23, 2026, pressing for immediate governance and operational change.
The letter cites a >96% share price decline since Seer’s 2020 IPO, 2025 revenue midpoint of $17.5M, cumulative cash used in operations of $138.8M and capex of $11.4M (total cash use $150.2M), a market cap of $110.5M vs. $251.2M net cash, and CEO Omid Farokhzad’s reported total compensation of $24.9M (2021–2024).
Seer (NASDAQ: SEER) will participate in US HUPO 2026 in St. Louis, Feb 21–25, showcasing the Proteograph Product Suite across posters, oral sessions, and a breakfast symposium on Feb 24. Presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and population-scale proteomics, highlighting deep, scalable nanoparticle-enabled proteomics.
Speakers include Sasha A. Singh, Nathan Basisty, Bruce Wilcox, and Mozhgan Boroumand; Singh reports quantifying >5,000 proteins from 75 µL plasma per sample.
Seer (Nasdaq: SEER) will participate in the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026. Management will take part in a fireside chat at 11:10 a.m. ET, with a live webcast and archived replay available on the company website.
Seer (Nasdaq: SEER) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Management will host a live webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and an archived replay will be available on the company investor website.
Seer (NASDAQ: SEER) announced a Nature Genetics study (Nov 2025) validating its Proteograph product suite for population-scale, peptide-level mass spectrometry proteomics. The GWAS profiled ~1,600 blood samples (discovery n=1,260; replication n=325), detecting 5,753 proteins and quantifying 1,980 in ≥80% of participants. Researchers identified 364 pQTLs, 102 replicated, and 35 novel signals. The study found up to one-third of affinity-based pQTLs from single platforms failed mass spectrometry replication, showing peptide-level measurement reduces epitope-related artifacts and improves confidence for drug-target and biomarker discovery.
Implication: peptide-level MS can distinguish true protein regulation from assay artifacts, strengthening translational proteogenomics.
Seer (Nasdaq: SEER) announced new data to be presented at the Human Proteome Organization (HUPO) World Congress 2025 on Nov 10–12, 2025. More than a dozen scientific presentations—including two invited talks in Seer’s breakfast symposium on Nov 10, 2025—showcase the Proteograph® platform applied across cardiovascular, oncology, and aging biology.
Highlights include deep plasma and tissue proteomics identifying candidate biomarkers for right ventricular failure, aging-related mediators from mouse serum, and multi-cancer and extracellular vesicle proteome studies, underscoring scalability and translational potential for population-scale research.